Rehabilitación Oral y Estética Dental
La práctica de Rosa María Ruiz gira en torno a Rehabilitación Oral y Estética Dental. Ejerce en Málaga. Cursó sus estudios de Odontología en Universidad de Granada en 2011.
Con el tiempo, ha sumado formación específica en implantología y cirugía oral. Su título de posgrado más reciente es el Máster en Cirugía Oral, Implantología y Rehabilitación Implantoprotésica (Universidad de Córdoba, 2020). Ha pasado por Universidad de Córdoba y Universidad de Granada.
Actualmente ejerce como ortodoncista en Clínica dental Torcaldent, Clínica dental Amelia Cano y Clínica dental Casabermeja en la provincia de Málaga. Antes desarrolló su actividad en Grupo dental Clinics y Clínica dental Unidental.
Su aportación al colectivo: firma 12 publicaciones científicas en revistas como Nefrología (English Edition) y Nefrología.
Explora su trayectoria
Máster en Cirugía Oral, Implantología y Rehabilitación Implantoprotésica
Máster · Universidad de Córdoba · Córdoba, España
Máster Propio en Clínica Odontológica Integral Avanzada e Implantología
Máster · Universidad de Granada · Granada, España
Grado / Licenciado en Odontología
Grado · Universidad de Granada · Granada, España
Clínica dental Torcaldent · Málaga, España
Clínica dental Casabermeja · Málaga, España
Clínica dental Amelia Cano · Málaga, España
Grupo dental Clinics · Málaga, España
Clínica dental Unidental · Málaga, España
Sin actividad docente registrada
Nefrología (English Edition)
Q3 · IF 1.059Autores · Guillermina Barril, Ana Avellón, Elena Jiménez Vibora, Luisa García Buey, Rosa María Ruiz-Calero Cendrero, A. García, José Ibeas, Cristina García Fernandez, Féderico García, Roberto Alcázar Arroyo
This position paper addresses the management of occult hepatitis B virus infection and isolated anti-HBc positivity in hemodialysis units. It reviews the clinical relevance of these serological profiles, their implications for infection control, and the interpretation of diagnostic testing in patients receiving chronic dialysis. The document provides guidance on screening, monitoring, preventive measures, and care coordination, aiming to support consistent risk assessment and safe clinical practice while minimizing the potential for hepatitis B virus transmission within dialysis settings.
Nefrología
Q4 · IF 0.623Autores · Guillermina Barril, Ana Avellón, Elena Jiménez Vibora, Luisa García Buey, Rosa María Ruiz-Calero Cendrero, A. García, José Ibeas, Cristina García Fernández, Federico García García, Roberto Alcázar Arroyo
Este documento de posicionamiento aborda el manejo de la infección oculta por el virus de la hepatitis B y de los pacientes con anticuerpos anti-HBc positivos en las unidades de hemodiálisis. Analiza las implicaciones diagnósticas, preventivas y asistenciales de estos perfiles serológicos en una población con especial vulnerabilidad infecciosa. Su enfoque busca orientar la evaluación clínica y microbiológica, las medidas de control de la transmisión, la vacunación y el seguimiento de los pacientes. Resulta útil para homogeneizar la práctica clínica y reforzar la seguridad en los centros de diálisis.
Nephrology Dialysis Transplantation
Q3 · IF 1.209Autores · Borja Quiroga, María José Soler, Alberto Ortíz, Carlos Jesús Jarava Mantecón, Virginia Olinda Gómez Pérez, A. Bordils, José Luis Lacueva, Antonio Franco, Pablo Delgado Conde, Patricia Muñoz Ramos, Carmen Calderón González, Juan Manuel Cazorla López, Jinny Sánchez-Rodríguez, Ana Sánchez Horrillo, Tania Monzón, Alba Leyva, José Antonio Muñoz Rojas, Ron T. Gansevoort, Patricia de Sequera, SENCOVAC collaborative network, Maria Teresa Jaldo Rodríguez, Rafael Lucena Valverde, Marta Puerta Carretero, Mayra Ortega Díaz, Daniel Gaitán Tocora, Esther Rodriguez Suárez, Alfredo José Sáenz Santolaya, Patricia Arribas Cobo, Tamar Talavan, Raquel Cerrajero Calero, Carolina Gracia-Iguacel, Emilio González‐Parra, Mônica Corso Pereira, Catalina Martín-Cleary, Ana Ramos-Verde, Martín Giorgi, Carmen Sánchez, Yohana Gil Giraldo, Ana Sánchez Horrillo, Pablo Ruano Suárez, Antonio Fernández Perpén, Andrés Fernández-Ramos, Laura Salanova Villanueva, Alejandra Cortiñas, Pablo A Díez Arias, Alicia Cabrera Cárden
BACKGROUND: There is scarce evidence on the fourth dose of severe acute respiratory syndrome coronavirus 2 vaccines in chronic kidney disease (CKD) patients. We evaluated the humoral response and effectivity of the fourth dose in the CKD spectrum: non-dialysis CKD (ND-CKD), haemodialysis (HD), peritoneal dialysis (PD) and kidney transplant (KT) recipients. METHODS: This is a prespecified analysis of the prospective, observational, multicentric SENCOVAC study. In patients with CKD who had received a complete initial vaccination and one or two boosters and had anti-Spike antibody determinations 6 and 12 months after the initial vaccination, we analysed factors associated with persistent negative humoral response and higher anti-Spike antibody titres as well as the efficacy of vaccination on coronavirus disease 2019 (COVID-19) severity. RESULTS: Of 2186 patients (18% KT, 8% PD, 69% HD and 5% ND-CKD), 30% had received a fourth dose. The fourth dose increased anti-Spike antibody titres in HD (P = .001) and ND-CKD (P = .014) patients and seroconverted 72% of previously negative patients. Higher anti-Spike antibody titres at 12 months were independently associated with repeated exposure to antigen (fourth dose, previous breakthrough infections), previous anti-Spike antibody titres and not being a KT recipient. Breakthrough COVID-19 was registered in 137 (6%) patients, 5% of whom required admission. Admitted patients had prior titres <620 UI/ml and median values were lower (P = .020) than in non-admitted patients. CONCLUSIONS: A fourth vaccine dose increased anti-Spike antibody titres or seroconverted many CKD patients, but those with the highest need for a vaccine booster (i.e. those with lower pre-booster antibody titres or KT recipients) derived the least benefit in terms of antibody titres. Admission for breakthrough COVID-19 was associated with low anti-Spike antibody titres.
Nephrology Dialysis Transplantation
Q3 · IF 1.209Autores · Borja Quiroga, María José Soler, Alberto Ortíz, Amparo Bernat, Ana Beatriz Muñoz Díaz, Carlos Jesús Jarava Mantecón, Virginia Olinda Gómez Pérez, Carmen Calderón González, Michal Červienka, Auxiliadora Mazuecos, Juan Manuel Cazorla, Manuel Carnerero Di Riso, Shaira Martínez, Mayra Ortega Díaz, Rafael Lucena Valverde, Marı́a Gabriela Márquez, Carolina Lancho Novillo, Emilio González Parra, Carolina Gracia-Iguacel, María Teresa Rodrigo De Tomas, María Cinta Aguilar Cervera, Martín Giorgi, Patricia Muñoz Ramos, Nicolás Macías Carmona, Néstor Toapanta, Secundino Cigarrán Guldris, Juan Carlos Ruiz, Raquel Santana Estupiñán, Marta Crespo, Blanca Villacorta Linaza, María Isabel Jimeno Martín, Laura Rodríguez-Osorio Jiménez, Sagrario Soriano, Dioné González Ferri, Maria Soledad Pizarro-Sánchez, Alejandra Yugueros González, Alba Leyva, José Antonio Muñoz Rojas, Ron T. Gansevoort, Patricia de Sequera, The SENCOVAC collaborative network, Marta Puerta Carretero, Daniel Gaitán Tocora, Ma Teresa Jal
SENCOVAC is a prospective multicentric study promoted by the Spanish Society of Nephrology (S.E.N.), which included four cohorts of adults with chronic kidney disease (CKD): kidney transplant recipients (KTRs), haemodialysis (HD), peritoneal dialysis (PD) and non-dialysis (ND)-CKD patients [glomerular filtration rate (GFR) <30 mL/min/1.73 m2] [1]. Participants were immunized with locally available vaccines [BNT162b2 (Pfizer-BioNTech®), mRNA-1273 (Moderna®), ChAdOx1-S (AstraZeneca®) or Ad26.COV.2 (Janssen®)] prescribed by regional health authorities unrelated to the study investigators. The present analysis (20 September 2021) predates booster doses. The primary objective was seroconversion after vaccination. Preliminary data showed lower anti-Spike antibody development after vaccination in KTRs than in other CKD patients [1] (Supplementary Material and methods). SENCOVAC included 3439 patients and analysed 28-day humoral immunity in 1061 patients and 3-month humoral immunity in 567 patients. Baseline characteristics of patients analysed 28 days and 3 months after vaccine completion are summarized in Supplementary data, Tables S1 and S2. At 28 days, 255 (24%) were KT, 103 (10%) PD, 610 (57%) HD and 93 (9%) ND-CKD patients (Figure 1A). At 3 months, 155 were KT (27%), 28 (5%) PD, 332 (59%) HD and 52 (9%) ND-CKD patients (Figure 1A). (A) Flow chart of the SENCOVAC study. (B) Proportion of patients with positive humoral response at baseline, 28 days and 3 months. (C) Negative and equivocal humoral response 3 months after completing vaccine schedule among patients with positive humoral response at 28 days. Data expressed as percentage of those who were positive at 28 days. (A) Flow chart of the SENCOVAC study. (B) Proportion of patients with positive humoral response at baseline, 28 days and 3 months. (C) Negative and equivocal humoral response 3 months after completing vaccine schedule among patients with positive humoral response at 28 days. Data expressed as percentage
Nephrology Dialysis Transplantation
Q3 · IF 1.209Autores · Borja Quiroga, María José Soler, Alberto Ortíz, Shaira Martínez Vaquera, Carlos Jesús Jarava Mantecón, Gustavo Useche, Marı́a Gabriela Márquez, Manuel Torralba Carnerero, Maria Teresa Jaldo Rodríguez, Patricia Muñoz Ramos, Juan Carlos Ruiz, Néstor Toapanta, Carolina Gracia-Iguacel, María Cinta Aguilar Cervera, Noelia Balibrea Lara, Alba Leyva, José Antonio Muñoz Rojas, Ron T. Gansevoort, Patricia de Sequera, SENCOVAC Collaborative Network, José Luis Pizarro León, Manuel Antonio Martínez García, Benaldina García Jiménez, Virginia Olinda Gómez Pérez, Juan de Dios Ramiro Moya, Diana López Espinosa, Alejandro Jiménez Herrador, Manuel Navarro Zurita, Leonardo Díaz Álvarez, Álvaro González Martínez, Sandra Báez Arroyo, Raquel Reina Fernández, Marlyn Janella Suárez Vargas, Rocío Calurano Casero, Amparo Bernat García, Ana Beatriz Muñoz Díaz, Carmen Santamaría de Miguel, Ángel Palacios, Brenda Henningsmeyer, Esther Orero Calve, José Lacueva Moya, Yurika Sato, Marta Serra Marín, Carolina Lancho
BACKGROUND: Chronic kidney disease (CKD) patients are at high-risk for severe coronavirus disease 2019 (COVID-19). The multicentric, observational and prospective SENCOVAC study aims to describe the humoral response and safety of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in CKD patients. Safety and immediate humoral response results are reported here. METHODS: Four cohorts of patients were included: kidney transplant (KT) recipients, and haemodialysis (HD), peritoneal dialysis (PD) and non-dialysis CKD patients from 50 Spanish centres. Adverse events after vaccine doses were recorded. At baseline and on Day 28 after the last vaccine dose, anti-Spike antibodies were measured and compared between cohorts. Factors associated with development of anti-Spike antibodies were analysed. RESULTS: A total of 1746 participants were recruited: 1116 HD, 171 PD, 176 non-dialysis CKD patients and 283 KT recipients. Most patients (98%) received mRNA vaccines. At least one vaccine reaction developed after the first dose in 763 (53.5%) and after the second dose in 741 (54.5%) of patients. Anti-Spike antibodies were measured in the first 301 patients. At 28 days, 95% of patients had developed antibodies: 79% of KT, 98% of HD, 99% of PD and 100% of non-dialysis CKD patients (P < 0.001). In a multivariate adjusted analysis, absence of an antibody response was independently associated with KT (odds ratio 20.56, P = 0.001) and with BNT162b2 vaccine (odds ratio 6.03, P = 0.023). CONCLUSION: The rate of anti-Spike antibody development after vaccination in KT patients was low but in other CKD patients it approached 100%, suggesting that KT patients require persistent isolation measures and booster doses of a COVID-19 vaccine. Potential differences between COVID-19 vaccines should be explored in prospective controlled studies.
International Urology and Nephrology
Q2 · IF 1.756Autores · Javier Deira, Silvia González Sanchidrián, André Rocha Rodrigues, Rosa María Ruiz-Calero Cendrero, Miguel Ángel Suárez, José María Sánchez Montalbán, Josefa Galán González, Olga Sánchez García, M Moreno, Juan Villa Rincón, María Antonia Fernández Solís, Clarencio Cebrián Andrada, Gaspar Tovar Manzano, Vanesa García‐Bernalt Funes, Alejandro Cives Muiño, Pedro Dorado
This study examines the incidence of COVID-19 and the factors associated with infection among patients treated in 13 hemodialysis units. Using data collected across multiple dialysis centers, the authors assess patient- and facility-related characteristics linked to SARS-CoV-2 occurrence. The findings may help identify vulnerable populations and modifiable risk factors in hemodialysis settings, informing infection-control strategies, surveillance protocols, and clinical decision-making to reduce transmission and protect patients requiring ongoing renal replacement therapy.
Nefrología (English Edition)
Q3 · IF 1.059Autores · María Victoria Martín Hidalgo-Barquero, Rosa María Ruiz-Calero Cendrero, Bárbara Cancho Castellano, María Cruz Cid Parra, Josefa Galán González
n e f r o l o g
Nefrología (English Edition)
Q3 · IF 1.059Autores · Bárbara Cancho Castellano, Rosa María Ruiz-Calero Cendrero, María Victoria Martín Hidalgo-Barquero, Rosa Díaz Campillejo, Cristina López Arnaldo, Nicolás Roberto Robles Pérez-Monteoliva
Persistent acute renal failure in a patient infected withPlasmodium malariae: the importance of renal biopsy ଝ Fracaso renal agudo
Nefrología (English Edition)
Q3 · IF 1.059Autores · Rosa María Ruiz-Calero Cendrero, Bárbara Cancho Castellano, María Victoria Martín Hidalgo-Barquero, María Cruz Cid Parra, Josefa Galán González, María Antonia Fernández Solís, Olga Sánchez García
Hepatitis B virus (HBV) is a serious world health problem.In year 2015, the estimated prevalence in the general population was 3.5%. 1 The morbidity and mortality associated with HBV-related chronic hepatitis is linked to the persistence of viral replication and progression to cirrhosis and/or hepatocellular carcinoma.One difficulty with HBV is the high risk of contamination, which magnifies the problem. 2 Patients on haemodialysis (HD) are at risk of HBV infection ; they are frequently transfused, and they are immunocompromised and subjected to invasive procedures with blood manipulation.They should therefore have serology testing and all seronegative patients need to be vaccinated. 3,4Thanks to this measure and isolation in the HD units according to
Nefrología
Q4 · IF 0.623Autores · Rosa María Ruiz-Calero Cendrero, Bárbara Cancho Castellano, María Victoria Martín Hidalgo-Barquero, María Cruz Cid Parra, Josefa Galán González, María Antonia Fernández Solís, Olga Sánchez García
Este artículo aborda la posible utilidad de investigar la infección oculta por el virus de la hepatitis B en pacientes sometidos a hemodiálisis. A partir de las particularidades epidemiológicas, inmunológicas y asistenciales de esta población, analiza los contextos clínicos en los que la búsqueda de marcadores virales adicionales podría estar justificada, incluso en ausencia de hallazgos serológicos convencionales. Su interés clínico radica en contribuir a la prevención de la transmisión nosocomial, la adecuada interpretación diagnóstica y la optimización de las medidas de vigilancia en las unidades de diálisis.
Nefrología
Q4 · IF 0.623Autores · Bárbara Cancho Castellano, Rosa María Ruiz-Calero Cendrero, María Victoria Martín Hidalgo-Barquero, Rosa Díaz Campillejo, Cristina López Arnaldo, Nicolás Roberto Robles Pérez-Monteoliva
Este artículo revisa aspectos actuales de la vigilancia epidemiológica de las infecciones virales en unidades de hemodiálisis. Aborda la relevancia de los sistemas de detección, notificación y seguimiento de casos para identificar riesgos de transmisión y orientar medidas preventivas en una población especialmente vulnerable. Asimismo, considera el papel de los protocolos de cribado, la monitorización microbiológica y la coordinación entre profesionales y autoridades sanitarias. Su utilidad clínica reside en apoyar la actualización de estrategias de control de infecciones y reforzar la seguridad asistencial en hemodiálisis.
Nefrología
Q4 · IF 0.623Autores · María Victoria Martín Hidalgo-Barquero, Rosa María Ruiz-Calero Cendrero, Bárbara Cancho Castellano, María Cruz Cid Parra, Josefa Galán González
Quimioterapia y reactivación oculta
Rehabilitación Oral y Estética Dental
México
Rehabilitación Oral y Estética Dental
Perú
Rehabilitación Oral y Estética Dental
Vizcaya · España
Rehabilitación Oral y Estética Dental
Madrid · España
Rehabilitación Oral y Estética Dental
Uruguay
Rehabilitación Oral y Estética Dental
Murcia · España
